Skip to main content

Biogen Value Stock - Dividend - Research Selection


ISIN: US09062X1037, WKN: 789617

Market price date: 16.05.2022
Market price: 198,38 USD

Biogen Fundamental data and company key figures of the share

Annual reports in USD
Key figures 06-02-2022
Cash flow
Net operating cash flow 3.639.000.000
Capital Expenditures -258.000.000
Free cash flow 3.380.999.936
Balance sheet
Total Equity 10.959.000.000
Liabilities & Shareholders equity 23.877.000.000
Income statement
Net income 1.556.100.000
Eps (diluted) 10,400
Diluted shares outstanding 148.600.000
Net sales/revenue 10.981.000.000

Fundamental ratios calculated on: 16-05-2022

Key figures 16-05-2022
Cash flow
P/C 8,10
P/FC 8,72
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization29.479.268.352,00 USD
CountryUnited States
IndicesMSCI World Index,NASDAQ 100,NASDAQ Comp.,S&P 500
Raw Data SourceUS GAAP in Millionen USD
Stock Split2001-01-18,3.0000/1.0000; 1999-12-21,2.0000/1.0000

Description of the company

Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases.


The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


How Many Biogen Inc. (NASDAQ:BIIB) Shares Do Institutions Own?

If you want to know who really controls Biogen Inc. ( NASDAQ:BIIB ), then you'll have to look at the makeup of its...

SEC filings reveal massive selling in media names, including Disney and Comcast

Leslie Picker joins the 'Halftime Report' to discuss what to expect from the SEC 13-F filings.

3 Dividend Stocks That Should Pay You for the Rest of Your Life

If you've got some cash stored up, consider yourself a wise investor -- and fortunate. Now could be a great time to put that cash to use toward an investment in these three Dividend Kings that could provide robust returns for a lifetime.

Top 5 1st Quarter Trades of Rhenman & Partners Asset Management AB


Biogen's Alex Cameron Discusses Biogen-MIT Biotech in Action

When the pandemic hit, in-person lessons at the Community Lab paused. That’s when Biogen-Lemelson-MIT Program Biotech in Action launched, providing online science and lab classes. Going virtual all...

BIIB July 1st Options Begin Trading

Staff article entitled BIIB July 1st Options Begin Trading, about stock options, from Stock Options Channel.

The Petri Dish: Biogen seeks accelerated approval for second Alzheimer's drug

Biogen and development partner Eisai are looking to get their next Alzheimer's drug to market using the FDA's accelerated approval pathway.

Biogen Now #253 Largest Company, Surpassing Weyerhaeuser

the online investor,BIIB,WY,

Biogen All but Throws in the Towel on Once-Promising Alzheimer's Drug

Company cuts commercial support of Aduhelm to minimum

Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment

Biogen stock popped Tuesday after the company's partner, Eisai, finished submitting its application for an experimental Alzheimer's drug.